Table 1.
Characteristics of the included studies
| Author,year | Study | Ethical approval | Sample Size | Gender (M/F) | Age, years | BMI(kg/m2) | Radiographic Classification (K-L) | Clinical Outcomes | Follow-up Periods | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRP + HA | PRP | HA | PRP + HA | PRP | HA | PRP + HA | PRP | HA | PRP + HA | PRP | HA | ||||||
| Michele Abate 2015 [17] | Co,R | Yes | 40 | 40 | – | 31/9 |
21/ 19 |
– |
56.7± 11.2 |
60.9 ± 9 | – | 23.7 ± 2 |
24.1± 1.6 |
– | II-III | VAS,AE | 6 ms |
| Wenxing Yu 2018 [18] | RCT | Yes | 96 | 104 | 88 | 50/46 |
50/ 54 |
48/40 |
46.5± 7.5 |
46.2 ± 8.6 | 51.5 ± 9.3 | – | – | – | I,II,III,IV |
WOMAC, AE |
12 ms |
| Yanqing Guo 2016 [19] | Co,P | Yes | 63 | 63 | – | 18/45 |
12/ 51 |
– |
61.2± 9.6 |
60.7 ± 10.1 | – | 24.2 ± 4.2 |
24.6± 3.9 |
– | I,II,III |
VAS,AE, WOMAC |
12 ms |
| Quanwei Ding 2017 [20] | RCT | Yes | 20 | 27 | – | 2/18 |
8/ 19 |
– |
56.75± 9.536 |
62.11 ± 12.5 | – |
24.31± 3.764 |
24.27 ± 3.636 | – | I,II,III |
WOMAC, VAS, Lequesne scores |
6 ms |
| Xin-liang Zhao 2018 [21] | RCT | Yes | 62 | 62 | – | 35/27 |
37/ 25 |
– | 55.73 ± 7.18 | 56.32 ± 8.13 | – | – | – | – | – | VAS | 1 month |
| Yanqing Guo 2018 [22] | RCT | Yes | 63 | 63 | – | 45/18 |
51/ 12 |
– | 61 ± 10 | 61 ± 10 | – | 24 ± 4 | 24 ± 4 | – | I,II,III | VAS,AE | 12 ms |
| Chenrong Ke 2016 [23] | RCT | Yes | 50 | 50 | 50 | 25/25 |
24/ 26 |
23/27 | 57.8 ± 6.9 | 59.3 ± 7.1 | 58.8 ± 6.4 | – | – | – | I,II,III,IV | Lequesne scores,AE | 12 ms |
Co Cohort study, P prospective study, R retrospective study, RCT randomized control trail, BMI body mass index, HA hyaluronic acid, K-L Kellgren and Lawrence grading scale, PRP platelet-rich plasma, AE Adverse events, VAS visual analog scale, WOMAC Western Ontario and McMaster Universities Arthritis Index, ms months